BE2011C041I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C041I2
BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
Authority
BE
Belgium
Application number
BE2011C041C
Other languages
French (fr)
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of BE2011C041I2 publication Critical patent/BE2011C041I2/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2011C041C 2000-05-26 2011-11-10 BE2011C041I2 (pm)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
BE2011C041I2 true BE2011C041I2 (pm) 2020-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C041C BE2011C041I2 (pm) 2000-05-26 2011-11-10

Country Status (41)

Country Link
EP (3) EP3029062A1 (pm)
JP (1) JP4328525B2 (pm)
KR (2) KR100889887B1 (pm)
CN (2) CN101255192A (pm)
AR (1) AR031699A1 (pm)
AT (1) ATE271066T1 (pm)
AU (2) AU2001263466C1 (pm)
BE (1) BE2011C041I2 (pm)
BR (1) BRPI0111191B8 (pm)
CA (1) CA2409748C (pm)
CY (2) CY2011019I2 (pm)
CZ (1) CZ304451B6 (pm)
DE (2) DE60104282T2 (pm)
DK (1) DK1248802T3 (pm)
EC (1) ECSP024365A (pm)
EE (2) EE05557B1 (pm)
EG (1) EG24459A (pm)
ES (2) ES2225549T3 (pm)
FR (1) FR11C0053I2 (pm)
GE (1) GEP20053658B (pm)
HK (1) HK1048126B (pm)
HU (2) HU228137B1 (pm)
IL (1) IL152315A (pm)
LT (1) LT5133B (pm)
LU (1) LU91902I2 (pm)
LV (1) LV12994B (pm)
MX (1) MXPA02011534A (pm)
MY (1) MY136113A (pm)
NO (2) NO330797B1 (pm)
PE (1) PE20011338A1 (pm)
PL (1) PL206267B1 (pm)
PT (1) PT1248802E (pm)
RU (1) RU2283847C2 (pm)
SI (1) SI1248802T1 (pm)
SK (1) SK288131B6 (pm)
TR (1) TR200402703T4 (pm)
TW (2) TWI319405B (pm)
UA (1) UA87432C2 (pm)
UY (1) UY26723A1 (pm)
WO (1) WO2001092337A2 (pm)
ZA (1) ZA200208944B (pm)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP3384924A1 (en) * 2000-07-03 2018-10-10 Bristol-Myers Squibb Company Uses of soluble ctla4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CN101044239B (zh) 2002-12-23 2010-12-08 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
ATE488600T1 (de) 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CN101675074B (zh) 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
ES2657220T3 (es) * 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ctla4 단백질 및 이의 용도
CN103534345A (zh) 2011-02-23 2014-01-22 安姆根有限公司 用于uvc暴射的细胞培养基及其相关方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
MX385969B (es) * 2012-05-11 2025-03-18 Medimmune Ltd Variantes de antígeno 4 del linfocito t citotóxico (ctla-4).
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
BR122020004385B1 (pt) 2014-01-13 2022-10-04 Amgen Inc Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
SG11201704351WA (en) 2014-12-01 2017-06-29 Amgen Inc Process for manipulating the level of glycan content of a glycoprotein
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN109715210B (zh) * 2016-09-19 2023-05-30 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
KR20250007033A (ko) 2017-04-20 2025-01-13 이제네시스, 인크. 유전자 변형 동물의 생성 방법
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
TW202128991A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗vegf蛋白組成物及其製備方法
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20230026434A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
KR20240125949A (ko) 2021-12-16 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 바이러스 불활성화를 위한 세제
JP2025507790A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP3722375B2 (ja) * 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ctla4レセプター、それを含有する融合タンパク質およびそれらの使用
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
EP3384924A1 (en) * 2000-07-03 2018-10-10 Bristol-Myers Squibb Company Uses of soluble ctla4 mutant molecules

Also Published As

Publication number Publication date
UA87432C2 (uk) 2009-07-27
CZ20023892A3 (cs) 2003-09-17
BRPI0111191B1 (pt) 2019-12-31
HUP0302201A3 (en) 2010-01-28
ZA200208944B (en) 2004-02-13
TWI314933B (en) 2009-09-21
WO2001092337A2 (en) 2001-12-06
HUS1300012I1 (hu) 2016-08-29
HK1048126B (en) 2005-03-04
LT2002114A (en) 2003-12-29
DE60104282D1 (de) 2004-08-19
EE200200659A (et) 2004-06-15
MY136113A (en) 2008-08-29
ATE271066T1 (de) 2004-07-15
EG24459A (en) 2009-07-16
EP3029062A1 (en) 2016-06-08
CA2409748A1 (en) 2001-12-06
HK1048126A1 (en) 2003-03-21
PE20011338A1 (es) 2002-01-13
DE122011100063I1 (de) 2012-06-14
NO20025656D0 (no) 2002-11-25
EE05458B1 (et) 2011-08-15
UY26723A1 (es) 2001-12-28
HK1071931A1 (en) 2005-08-05
SI1248802T1 (en) 2005-02-28
EP1536234B1 (en) 2016-03-16
CN1441810A (zh) 2003-09-10
GEP20053658B (en) 2005-11-10
EE05557B1 (et) 2012-08-15
BR0111191A (pt) 2004-07-06
CA2409748C (en) 2008-09-16
EP1536234A3 (en) 2009-06-03
EE201100050A (et) 2011-10-17
CY2011019I1 (el) 2016-12-14
PT1248802E (pt) 2004-11-30
EP1248802B9 (en) 2005-05-11
CN1309735C (zh) 2007-04-11
ES2225549T3 (es) 2005-03-16
JP2004511213A (ja) 2004-04-15
SK15702002A3 (sk) 2004-01-08
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
AU2001263466B2 (en) 2006-04-27
KR20030009502A (ko) 2003-01-29
KR100889887B1 (ko) 2009-03-24
PL366231A1 (en) 2005-01-24
EP1536234A2 (en) 2005-06-01
AR031699A1 (es) 2003-10-01
JP4328525B2 (ja) 2009-09-09
MXPA02011534A (es) 2004-08-12
LV12994B (en) 2003-08-20
NO20025656L (no) 2002-11-25
HUP0302201A2 (hu) 2003-10-28
ECSP024365A (es) 2003-03-31
DK1248802T3 (da) 2004-11-15
HU228137B1 (en) 2012-12-28
WO2001092337A3 (en) 2002-05-10
IL152315A0 (en) 2003-05-29
NO2011027I2 (pm) 2011-12-15
FR11C0053I2 (fr) 2013-01-11
RU2283847C2 (ru) 2006-09-20
IL152315A (en) 2010-04-15
ES2571852T3 (es) 2016-05-27
FR11C0053I1 (pm) 2012-01-13
BRPI0111191B8 (pt) 2021-05-25
CN101255192A (zh) 2008-09-03
NO330797B1 (no) 2011-07-18
EP1248802B1 (en) 2004-07-14
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
TR200402703T4 (tr) 2004-11-22
KR100895134B1 (ko) 2009-05-04
NO2011027I1 (no) 2012-01-09
CZ304451B6 (cs) 2014-05-14
AU2001263466C1 (en) 2006-10-26
AU6346601A (en) 2001-12-11
DE60104282T2 (de) 2005-10-13
SK288131B6 (sk) 2013-10-02
TW200906857A (en) 2009-02-16
TWI319405B (en) 2010-01-11
LT5133B (lt) 2004-05-25
PL206267B1 (pl) 2010-07-30
CY1117625T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
BE2016C018I2 (pm)
BE2014C019I2 (pm)
NO2011027I2 (pm)
BE2010C008I2 (pm)
JP2003509775A5 (pm)
BE2010C009I2 (pm)
BE2009C057I2 (pm)
BE2010C018I2 (pm)
JP2003503097A5 (pm)
AU2000236815A8 (pm)
AU2000236813A8 (pm)
JP2001197775A5 (pm)
JP2000280854A5 (pm)
JP2002010108A5 (pm)
JP2002079672A5 (pm)
BE2014C025I2 (pm)
JP2002193110A5 (pm)
JP2003519584A5 (pm)
JP2003509678A5 (pm)
JP2002165882A5 (pm)
JP2001228500A5 (pm)
JP2001255510A5 (pm)
JP2001340322A5 (pm)
JP2002090847A5 (pm)
JP2001238443A5 (pm)